Get startedLog in
    Picture of Chosa Oncology AB logo

    CHOSA — Chosa Oncology AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Rhovac AB Says Phase IIb Study In Prostate Cancer Failed To Meet Its Primary Endpoint

    Picture of Chosa Oncology AB logoChosa Oncology AB
    29/05/2022 18:55
    May 29 (Reuters) - RhoVac AB  RHOVAC.TE :
    * RHOVAC'S PHASE IIB STUDY IN PROSTATE CANCER , BRAVAC,
FAILED TO
MEET ITS PRIMARY ENDPOINT
    * WILL NOW EXECUTE ON A COST MINIMISATION CONTINGENCY PLAN,
WHILE
CONDUCTING FURTHER ANALYSES OF RESULTS

Source text for Eikon:  ID:nWkr7fLmWS 
Further company coverage:  RHOVAC.TE 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Chosa Oncology AB

    See all news